Stereotactic body radiation therapy for centrally-located lung tumors

The application of high-dose irradiation to centrally-located lung tumors is generally considered to be of high risk in causing bronchial injury. The aim of the present retrospective study was to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) for patients with cent...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2014-04, Vol.7 (4), p.1292-1296
Main Authors: SHEN, GE, WANG, YING-JIE, SHEN, WEN-JIANG, ZHOU, ZHEN-SHAN, WANG, JUN-LIANG, SHENG, HONG-GUO, DONG, DA-PENG, ZHOU, MING, YANG, GANG, WANG, QIN-WEN, ZENG, YANJUN
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Care and treatment
centrally-located
Chemotherapy
Esophagus
Lung cancer
lung tumor
Lung tumors
Metastasis
Methods
Multivariate analysis
Oncology
Oncology, Experimental
Pathology
Patient outcomes
Patients
Radiation therapy
Radiotherapy
stereotactic body radiation therapy
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The application of high-dose irradiation to centrally-located lung tumors is generally considered to be of high risk in causing bronchial injury. The aim of the present retrospective study was to investigate the safety and efficacy of stereotactic body radiation therapy (SBRT) for patients with centrally-located lung tumors. In total, 28 patients who underwent SBRT for lung tumors within 2 cm of a major bronchus were retrospectively analyzed. The median total dose prescribed was 45 Gy (range, 36.3-52.5 Gy), the median fraction was 12 (range, 10-15) and the median dose per fraction was 3.6 Gy (range, 3-5 Gy). The median follow-up period for the surviving patients was 14 months (range, 10-41 months). The local control rate of SBRT was 100%, with a complete response (CR) rate of 32.1% (9/28); a partial response (PR) rate of 50% (14/28) and a stable disease (SD) rate of 17.9% (5/28). In total, 15 patients survived and 13 patients succumbed; 11 patients succumbed to tumor progression, one to congestive heart failure and one to a brain hemorrhage. The main side-effects included grade 2 esophagitis (17.9%; 5/28) atelectasis (10.7%; 3/28) and grade 2 late radiation pneumonitis (7.1%; 2/28). Severe late toxicity (≥ grade 3) was not observed in any patient. SBRT is an effective and safe therapy for centrally-located lung tumors.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2014.1815